# US 2004/0082805 A1 · Cyclooctanone derivatives and cyclodecanone derivative, and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082805 A1
- Document ID: US20040082805A1
- Status: Published application
- Kind: A1
- Application number: 10/473,568
- Filed: 2003-09-29
- Published: 2004-04-29
- Earliest claimed: 2003-09-29
- Assignees: Eisai Co., Ltd.
- Inventors: Yoshihito Eguchi; Ken-cihi Chiba; Masaki Goto; Hiroshi Obaishi; Yoshikazu Kuboi
- Web page: https://patentgrep.com/patent/US20040082805A1

## CPC

- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61K 31/12: Ketones
- A61K 31/235: having an aromatic ring attached to a carboxyl group
- A61K 31/24: having an amino or nitro group
- A61K 31/4402: only substituted in position 2, e.g. pheniramine, bisacodyl
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 13/12: of the kidneys
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 49/657: containing six-membered aromatic rings
- C07C 49/747: containing six-membered aromatic rings
- C07C 49/753: containing ether groups, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] groups
- C07C 205/57: having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07D 207/12: Oxygen or sulfur atoms
- C07D 453/02: containing not further condensed quinuclidine ring systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

The present invention provides a compound which has cytokine production inhibitory activity and is useful for the treatment of diseases which is associated with cytokine. The compound is represented by the following general formula (I) [wherein A represents a cyclic group which may be substituted; the partial structure -DE- represents a group represented by —CH2CH2— or —CH═CH—; W represents a group represented by —CH2—, —CH2CH2—, —CH═CH— or —CH═; the partial structure >XY—represents a group represented by >CH—(CH2)n—, >C═CH—, >CH—CH2—CH(OH)—, >CH—CH2—C(═O)—, >CH—O— or >CH—O—CO—, provided that when W is —CH═, then XY— represents C—(CH2)p—; Z represents a divalent aliphatic hydrocarbon group; R1 and R2, which may be the same or different, each represents a hydrogen atom, or a hydroxyl, alkoxy or alkoxyalkoxy group; m is an integer of 0 or 1].

## Claims

### Claim 1

A compound represented by the following general formula (1) [wherein A represents a five- to fourteen membered aromatic group, which may be substituted, or a cycloaliphatic hydrocarbon group, which may be substituted, having from three to ten carbon atoms;
the partial structure -DE- represents a group represented by —CH2CH2— or —CH═CH—;
W represents a group represented by —CH2—, —CH2CH2—, —CH═CH— or —CH═; the partial structure >XY— represents a group represented by the formula >CH—(CH2)n—, wherein n is an integer of 0 or 1; >C═CH—; >CH—CH2—CH(OH)—; >CH—CH2—C(═O)—; >CH—O—; or >CH—O—CO—, provided that when W is —CH═, then XY— represents the formula C—(CH2)p—, wherein p is an integer of 0 or 1;
Z represents a divalent aliphatic hydrocarbon group having from zero to eight carbon atoms;
R1 and R2, which may be the same or different, each represents a hydrogen atom, a hydroxyl group, a C1-6 alkoxy group or a C1-6 alkoxy-C1-6 alkoxy group, provided that when R2 represents a hydrogen atom, R1 also represents a hydrogen atom;
m is an integer of 0 or 1, and when w represents —CH2— or —CH═, then m is 0, and when w represents —(CH2)2— or —CH═CH—, then m is 1;
with exception of the compound represented by the following formula X; or salts thereof or hydrates thereof:
26

### Claim 2 (depends on 1)

The compound according to claim 1, wherein A is a five- to fourteen-membered aromatic heterocyclic group, which may be substituted; or salts thereof or hydrates thereof.

### Claim 3 (depends on 1)

The compound according to claim 1, wherein A is a phenyl, naphthyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thienyl, furyl, oxazolyl or thiazolyl group, each of which may be substituted; or salts thereof or hydrates thereof.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein A is a phenyl or pyridyl group, each of which may be substituted; or salts thereof or hydrates thereof.

### Claim 5 (depends on 1, 2, 3, 4)

The compound according to any one of claims 1 to 4, wherein R2 and/or R1 are a hydroxyl group; or salts thereof or hydrates thereof.

### Claim 6 (depends on 1, 2, 3, 4)

The compound according to any one of claims 1 to 4, wherein R1 and/or R2 are a C1-6 alkoxy-C1-6 alkoxy group; or salts thereof or hydrates thereof.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The compound according to any one of claims 1 to 6, wherein the partial structure -DE- represents a group represented by —CH═CH—; or salts thereof or hydrates thereof.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound according to any one of claims 1 to 7, wherein W represents a group represented by —CH2— or —CH═, and wherein m is 0; or salts thereof or hydrates thereof.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7)

The compound according to any one of claims 1 to 7,wherein W represents a group represented by —(CH2)2— or —CH═CH—, and wherein m is 1; or salts thereof or hydrates thereof.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The compound according to any one of claims 1 to 9, wherein the partial structure >XY— represents a group represented by the formula >CH—(CH2)n— (wherein n is an integer of 0 or 1), the formula >C═CH—, the formula >CH—CH2—CH(OH)—, the formula >CH—CH2—C(═O)— or the formula >CH—O—; or salts thereof or hydrates thereof.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The compound according to any one of claims 1 to 9, wherein the partial structure >XY— represents a group represented by the formula >CH—(CH2)n— (wherein n is an integer of 0 or 1); or salts thereof or hydrates thereof.

### Claim 12 (depends on 1)

The compound according to claim 1, wherein A is an aromatic or cycloaliphatic group which may have one to three groups selected from a hydroxyl group or an alkoxy group which may be substituted; or salts thereof or hydrates thereof.

### Claim 13 (depends on 1)

The compound according to claim 1, wherein the compound is selected from 5-benzyl-1-cyclooctanone, 5-phenethyl-1-cyclooctanone, 5-(2-pyridylmethyl)-1-cyclooctanone, 5-[2-(2-hydroxyphenyl)ethyl]-1-cyclooctanone, 5-[2-(2-hydroxy-4-methoxyphenyl)ethyl]-1-cyclooctanone, 5-benzyl-2-cycloocten-1-one, 5-phenethyl-2-cycloocten-1-one, 5-(2-pyridylmethyl)-2-cycloocten-1-one, 5-[2-(2-hydroxy-4-methoxyphenyl)ethyl]-2-cycloocten-1-one, 5-benzyl-8-hydroxy-2-cycloocten-1-one, 5-benzyl-7,8-dihydroxy-2-cycloocten-1-one, 2,3-dihydroxy-5-[2-(2-hydroxyphenyl)ethyl]-1-cyclooctanone, 5-oxocyclooctyl=benzoate, 5-oxo-3-cyclooctenyl=benzoate, 5-oxocyclooctyl=2-hydroxybenzoate, 5-oxo-3-cyclooctenyl=2-hydroxybenzoate, 5-oxo-3-cyclooctenyl=(2-methoxymethoxy)benzoate, 5-oxocyclooctyl=(2-hydroxy-4-methoxy)benzoate, 5-oxo-3-cyclooctenyl=(2-hydroxy-4-methoxy)benzoate, 5-oxo-3-cyclooctenyl=2-nitrobenzoate, 3,4-dihydroxy-5-oxocyclooctyl=benzoate, 6,7-dihydroxy-5-oxo-3-cyclooctenyl=benzoate, 6,7-dihydroxy-5-oxo-3-cyclooctenyl=2-hydroxybenzoate, 3,4-dihydroxy-5-oxocyclooctyl=(2-methoxymethoxy)benzoate, 3,4-dihydroxy-5-oxocyclooctyl=(2-hydroxy-4-methoxy)benzoate, 6,7-dihydroxy-5-oxo-3-cyclooctenyl=(2-hydroxy-4-methoxy)-benzoate, 6,7-dihydroxy-5-oxo-3-cyclooctenyl=2-nitrobenzoate, 6-benzyl-1-cyclodecanone, 6-phenethyl-1-cyclodecanone, 6-(2-pyridylmethyl)-1-cyclodecanone, 6-[2-(2-hydroxyphenyl)ethyl]-1-cyclodecanone, 6-[2-(2-hydroxy-4-methoxyphenyl)ethyl]1-cyclodecanone, 6-benzyl-2-cyclodecen-1-one, 6-phenethyl-2-cyclodecen-1-one, 6-(2-pyridylmethyl)-2-cyclodecen-1-one, 6-[2-(2-hydroxy-4-methoxyphenyl)ethyl]-2-cyclodecen-1-one, 6-benzyl-10-hydroxy-2-cyclodecen-1-one, 6-benzyl-9,10-dihydroxy-2-cyclodecen-1-one, 9,10-dihydroxy-6-phenethyl-cyclodecen-1-one, 9,10-dihydroxy-6-[2-(2-hydroxyphenyl)ethyl]cyclodecen-1-one, 6-oxocyclodecyl=benzoate, 6-oxo-4-cyclodecenyl=benzoate, 6-oxocyclodecyl=2-hydroxybenzoate, 6-oxo-4-cyclodecenyl=2-hydroxybenzoate, 6-oxo-4-cyclodecenyl=4-methoxybenzoate, 6-oxocyclodecyl=(2-hydroxy-4-methoxy)benzoate, 6-oxo-4-cyclodecenyl=(2-hydroxy-4-methoxy)benzoate, 6-oxocyclodecyl=2-nitorobenzoate, 6-oxo-4-cyclodecenyl=2-nitrobenzoate, 4,5-dihydroxy-6-oxocyclodecyl=benzoate, 7,8-dihydroxy-6-oxo-4-cyclodecenyl=benzoate, 7,8-dihydroxy-6-oxo-4-cyclodecenyl=(2-methoxymethoxy)-benzoate, 7,8-dihydroxy-6-oxo-4-cyclodecenyl=4-methoxybenzoate, 7,8-dihydroxy-6-oxo-4-cyclodecenyl=(2-hydroxy-4-methoxy)-benzoate, 4,5-dihydroxy-6-oxocyclodecyl=2-nitrobenzoate, or 7,8-dihydroxy-6-oxo-4-cyclodecenyl=2-nitrobenzoate; or salts thereof or hydrates thereof.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising the compound according to claim 1 or salts thereof or hydrates thereof.

### Claim 15 (depends on 1)

An agent for inhibiting cytokine production, wherein the agent comprises the compound according to claim 1.

### Claim 16 (depends on 1)

An agent for inhibiting TNF-α production, IL-6 production or IL-2 production, wherein the agent comprises the compound according to claim 1.

### Claim 17 (depends on 1)

An agent for treating or preventing diseases which is associated with cytokine, wherein the agent comprises the compound according to claim 1.

### Claim 18 (depends on 1)

An agent for treating or preventing chronic rheumatoid arthritis, ulcerative colitis, glomerulonephritis, osteoarthritis, atopic dermatitis, endotoxin shock, sepsis, diabetes, viral hepatitis, mesangial proliferative glomerulonephritis, adenoviral ophthalmia or AIDS, wherein the agent comprises the compound according to claim 1.
